CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab

J J Ifthikharuddin; L A Mieles; J D Rosenblatt; C K Ryan; D M Sahasrabudhe

doi:10.1002/1096-8652(200010)65:2<171::aid-ajh14>3.0.co;2-z

CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab

Am J Hematol. 2000 Oct;65(2):171-3. doi: 10.1002/1096-8652(200010)65:2<171::aid-ajh14>3.0.co;2-z.

Authors

J J Ifthikharuddin¹, L A Mieles, J D Rosenblatt, C K Ryan, D M Sahasrabudhe

Affiliation

¹ Department of Hematology-Oncology, University of Rochester, Strong Memorial Hospital, Rochester, New York 14642, USA. j.j_ifthikharuddin@urmc.rochester.edu

PMID: 10996837
DOI: 10.1002/1096-8652(200010)65:2<171::aid-ajh14>3.0.co;2-z

Abstract

B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment.

Publication types

Case Reports
Review

MeSH terms

Adult
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 / blood*
Child
Female
Herpesvirus 4, Human / genetics
Humans
Infant
Intestine, Small / transplantation
Liver Transplantation / adverse effects
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / etiology
Lymphoma, Large B-Cell, Diffuse / virology
Lymphoproliferative Disorders / drug therapy
Lymphoproliferative Disorders / etiology*
Lymphoproliferative Disorders / virology
Male
Middle Aged
Organ Transplantation / adverse effects*
Postoperative Complications / drug therapy
Postoperative Complications / etiology
RNA, Messenger / blood
Rituximab
Time Factors

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
RNA, Messenger
Rituximab